Oral Estradiol Cost in North Carolina 2026

At a glance
- Average retail cash price / ~$15/month in NC (2026)
- Manufacturer list price / ~$40/month
- NC Medicaid coverage for menopausal symptoms / Not covered
- 503A compounded estradiol (NC-licensed pharmacy) / Available; often $0 out-of-pocket
- Telehealth prescribing / Legal in North Carolina
- Typical dose form / Oral tablet, once daily
- Prescription required / Yes (Schedule III-exempt; Rx-only)
- GoodRx / SingleCare savings / Can reduce cash price further, sometimes to $10 or less
What Is Oral Estradiol and Why Does Price Vary So Much?
Oral estradiol is a bioidentical form of 17-beta estradiol taken as a daily tablet, approved by the FDA for moderate-to-severe vasomotor symptoms of menopause, vulvar and vaginal atrophy, and hypoestrogenism [1]. Because dozens of generic manufacturers now supply the U.S. market, retail prices swing widely depending on the pharmacy, the dispensing quantity, and whether a discount card is applied.
The FDA-approved label covers tablets in 0.5 mg, 1 mg, and 2 mg strengths [1]. Brand-name Estrace carries a higher list price, but generics dominate the North Carolina retail market. The manufacturer list price for a 30-day supply of a generic sits around $40, yet actual cash transactions at NC pharmacies in 2026 average closer to $15 per month once pharmacy-level pricing and discount cards are factored in.
Several variables drive the remaining gap between pharmacies: wholesaler acquisition cost, individual pharmacy markup policy, whether the pharmacy participates in a 340B program, and the patient's use (or non-use) of a savings card. A patient paying full retail at a major chain without any coupon may see $30 to $40 on their receipt. The same prescription at an independent or warehouse-club pharmacy with a SingleCare card can drop to $9 or $10 for a 30-count.
Generic estradiol tablets have been on the market long enough that price competition is mature. That maturity is the main reason the drug is accessible to most cash-pay patients in North Carolina, even without insurance.
[Sources: 1]
North Carolina Medicaid Coverage for Oral Estradiol
North Carolina Medicaid does not cover oral estradiol prescribed specifically for menopausal vasomotor symptoms. The NC Medicaid preferred drug list restricts estrogen coverage primarily to diagnoses tied to type 2 diabetes management or documented hypoestrogenism resulting from surgical menopause, primary ovarian insufficiency, or similar endocrine conditions. Menopausal hot flashes and night sweats alone do not qualify under current NC Medicaid criteria.
This matters for roughly 1.5 million North Carolinians currently enrolled in Medicaid managed care plans, many of whom are women in the perimenopausal and postmenopausal age range [2]. If a qualifying diagnosis such as premature ovarian insufficiency or surgical menopause is present, the prescriber can document that diagnosis code on the prior authorization request, which may reveal coverage. Without it, the claim will be denied.
The Endocrine Society's 2022 clinical practice guideline states, "Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy symptomatic women younger than 60 years or within 10 years of menopause onset" [3]. That clinical consensus has not yet translated into a Medicaid benefit expansion in North Carolina.
For patients who are Medicaid-enrolled and receive a denial, the next step is to explore manufacturer patient-assistance programs, 340B-affiliated community health centers, or 503A compounding options described below.
Cash-Pay Pricing at North Carolina Retail Pharmacies
The average cash-pay price across North Carolina retail pharmacies in 2026 is approximately $15 per 30-day supply of generic oral estradiol. That figure sits well below the national average for many branded hormonal medications, and it makes oral estradiol one of the more affordable prescription options for perimenopausal symptom management.
Pricing by pharmacy type varies in predictable patterns:
Large chain pharmacies (CVS, Walgreens, Rite Aid). Without a discount card, expect $25 to $40 for a 30-count. With GoodRx or SingleCare, prices at many NC locations drop to $10 to $18 depending on the specific store and tier.
Warehouse clubs (Costco, Sam's Club pharmacy). Costco's Kirkland-branded generic pricing and its posted cash prices are consistently among the lowest in NC, often $9 to $12 without any coupon.
Independent pharmacies. Prices vary considerably, from as low as $8 at pharmacies that have negotiated favorable contracts to over $35 at some independents without discount-card participation. Always call ahead.
Mail-order (90-day supply). Ordering a 90-day supply through a PBM-affiliated mail-order pharmacy typically reduces the per-month cost by 10 to 20 percent compared with a 30-day retail fill. For a stable, long-term prescription, this is usually the lowest-friction option after compounding.
Dose also affects price. Estradiol 1 mg tablets are the most commonly dispensed strength and carry the most competitive pricing. The 2 mg tablet has fewer generic suppliers and may cost $5 to $10 more per fill at some pharmacies.
Compounded Oral Estradiol in North Carolina: Legality and Cost
Compounded oral estradiol is legal in North Carolina when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The term "503A" refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare medications for individual patients [5].
North Carolina's Board of Pharmacy licenses and inspects 503A facilities operating within the state. Out-of-state 503A pharmacies can ship compounded estradiol into North Carolina as long as they hold the appropriate non-resident pharmacy permit from the NC Board of Pharmacy and the preparation is patient-specific [6].
On the cost side, compounded oral estradiol may be available at little to no out-of-pocket cost through certain telehealth platforms and compounding-pharmacy partnerships. Some platforms bundle the cost of the compound into a membership or consultation fee, so the effective per-month medication cost registers as $0. Patients should ask explicitly what is included in any quoted price and whether the compound contains estradiol alone or in combination with progesterone.
The HealthRX clinical team uses the following decision framework when advising North Carolina patients on compounded versus commercial estradiol:
- FDA-approved generic first. If the patient can fill a 1 mg or 2 mg commercial generic for $15 or less per month with a discount card, the regulatory-risk profile is lower and the formulation is pharmaceutical-grade.
- Compounding for dose flexibility. Doses below 0.5 mg or above 2 mg are not available commercially. Patients requiring 0.25 mg for titration or 4 mg for post-oophorectomy replacement may need a compounded preparation.
- Compounding for excipient sensitivity. Patients with documented allergies to fillers in commercial tablets (lactose, corn starch) may benefit from a custom compound.
- Cost-driven compounding. When the effective cash cost of the compound through a licensed telehealth-pharmacy partnership is lower than the retail cash price, and the pharmacy is NC-Board-licensed, this is clinically acceptable provided the patient undergoes appropriate screening.
The FDA has noted that compounded products do not undergo the same pre-market review for safety, efficacy, and manufacturing quality as FDA-approved drugs [5]. That difference should be part of the informed-consent conversation.
Insurance Coverage for Oral Estradiol in North Carolina
Commercial insurance coverage for oral estradiol in North Carolina is inconsistent but generally more favorable than Medicaid. Most major plan types cover at least one generic estradiol tablet on their formulary, usually at Tier 1 or Tier 2.
NC State Health Plan (State Employees). The NC State Health Plan covers generic estradiol tablets for enrolled state employees and dependents, typically at a $10 to $20 copay for a 30-day supply depending on the plan tier selected.
ACA marketplace plans. Under the Affordable Care Act, most marketplace plans in North Carolina are required to cover FDA-approved contraceptives without cost-sharing, but menopausal hormone therapy is a separate category and not universally zero-cost. Estradiol appears on most silver- and gold-tier formularies at Tier 1 or Tier 2. Patient out-of-pocket costs range from $0 to $30 per month after deductible, depending on the plan.
Employer-sponsored commercial plans. BlueCross BlueShield of North Carolina, Aetna, Cigna, and UnitedHealthcare all include generic estradiol on standard formularies in North Carolina. The Tier 1 generic copay on most employer plans is $5 to $15 per 30-day fill. Prior authorization is rarely required for standard doses.
Medicare Part D. Women 65 and older on Medicare may access estradiol through Part D prescription drug plans. Coverage depends on the specific plan's formulary. During the standard coverage phase in 2026, a Tier 1 generic copay is typically $0 to $10. Patients in the catastrophic phase pay no more than $2 for Tier 1 generics under current Part D redesign rules.
If your insurance denies coverage, request a formulary exception citing the prescribing physician's clinical documentation. Denials based on "not medically necessary" can often be overturned when the prescriber submits records showing documented vasomotor symptoms, FSH levels, or a menopausal diagnosis.
Clinical Evidence Supporting Oral Estradiol Use
Understanding cost is only half the picture. Prescribers and patients in North Carolina should also know what the evidence says about oral estradiol's effectiveness and safety profile, since that evidence shapes whether the drug is worth the price paid.
The Women's Health Initiative (WHI), published in JAMA in 2002 (N=16,608), remains the landmark trial examining oral conjugated equine estrogens combined with medroxyprogesterone acetate [4]. The estrogen-plus-progestin arm showed a hazard ratio of 1.26 for breast cancer (95% CI 1.00 to 1.59) and increased cardiovascular event risk in older postmenopausal women [4]. Subsequent re-analyses stratified by age at initiation revealed that women who began hormone therapy within 10 years of menopause onset, or before age 60, had a more favorable benefit-risk profile, a finding now embedded in both the Menopause Society's 2023 position statement and the Endocrine Society's 2022 guideline [3].
Oral 17-beta estradiol (the bioidentical form dispensed as generic estradiol tablets) differs pharmacokinetically from conjugated equine estrogens. After oral ingestion, estradiol undergoes first-pass hepatic metabolism, generating estrone and estrone sulfate. This first-pass effect raises SHBG and may have a modest effect on coagulation factors, which is why some clinicians prefer transdermal delivery in patients with elevated clotting risk [9]. For the majority of healthy women without personal or strong family history of venous thromboembolism, oral estradiol at standard doses (0.5 to 2 mg daily) carries a manageable risk profile when prescribed and monitored appropriately.
The Menopause Society's 2023 statement reads: "For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [10].
Effective symptom relief is documented at doses as low as 0.5 mg daily for mild to moderate vasomotor symptoms, with most patients reaching adequate symptom control between 1 mg and 2 mg daily. Dose adjustments are made at 4-to-8-week intervals based on symptom diary and, where indicated, serum estradiol levels.
Telehealth Access to Oral Estradiol in North Carolina
Telehealth prescribing of oral estradiol is fully legal in North Carolina in 2026. A prescriber licensed in North Carolina may conduct an audio-video or, in some cases, synchronous phone visit, evaluate a patient for menopausal hormone therapy, and transmit an electronic prescription to any pharmacy the patient chooses, including a 503A compounding pharmacy.
North Carolina does not require an in-person visit before prescribing estradiol. The prescriber must conduct a clinically appropriate evaluation, document symptoms, review contraindications, and obtain informed consent. These requirements apply equally to telehealth and in-office encounters.
HealthRX and similar platforms serve North Carolina patients through licensed prescribers who follow this protocol. After a telehealth visit, a prescription for generic estradiol 1 mg tablets can typically be sent to a local NC pharmacy (for same-day or next-day pickup) or to a mail-order or compounding pharmacy for delivery.
For patients without insurance, the telehealth consultation fee varies by platform, generally $49 to $150 for an initial visit. Adding the $10 to $15 monthly medication cost, the total first-month outlay typically lands between $60 and $165. Follow-up visits are usually lower, $25 to $75, making the ongoing monthly cost primarily the pharmacy price after the first visit.
The North Carolina Medical Board's telemedicine policy, updated in 2022, requires that telehealth encounters meet the same standard of care as in-person visits, including appropriate follow-up and the ability to refer patients to in-person care when clinically indicated [11].
[Sources: 11]
Discount Programs and Patient Assistance in North Carolina
Several programs can reduce or eliminate out-of-pocket costs for oral estradiol in North Carolina, independent of insurance status.
GoodRx and SingleCare. These free discount cards are accepted at most North Carolina retail pharmacies. For generic estradiol 1 mg (30 tablets), GoodRx prices in NC range from approximately $9 to $18 depending on the pharmacy and zip code. SingleCare frequently matches or beats GoodRx pricing at certain chains. Neither card requires membership or income verification. The patient simply presents the card (or app-generated barcode) at the pharmacy counter and pays the negotiated price.
Manufacturer patient-assistance programs. Most manufacturers of generic estradiol do not operate branded patient-assistance programs because generics carry low margins. However, Pfizer (which markets Estrace brand) offers the Pfizer Patient Assistance Program (PAP) for qualifying low-income patients on brand-name products.
340B community health centers. Federally Qualified Health Centers (FQHCs) in North Carolina participating in the 340B Drug Pricing Program can dispense covered outpatient drugs, including estradiol, at significantly reduced prices to qualifying patients (generally those at or below 200 percent of the federal poverty level). North Carolina has over 50 FQHC sites across the state [12].
NC Medicaid prior authorization appeal. As described above, patients with a qualifying diagnosis (primary ovarian insufficiency, surgical menopause, hypoestrogenism) should request a prior authorization appeal with supporting documentation rather than accepting the initial denial.
Drug company co-pay cards. Brand-name Estrace and certain authorized generics may offer co-pay assistance cards that reduce commercial-insurance patient cost-sharing to as low as $0 per fill. These cards are not usable by Medicare or Medicaid beneficiaries under federal law.
[Sources: 12]
Who Should Not Take Oral Estradiol
Cost and access are moot if a patient has a contraindication. The FDA label for estradiol oral identifies the following absolute contraindications: undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia, active or history of deep vein thrombosis or pulmonary embolism, active or recent (within the past year) arterial thromboembolic disease, known anaphylactic reaction or angioedema with estradiol, known liver impairment or disease, and known or suspected pregnancy [1].
Patients with a personal history of hormone-receptor-positive breast cancer should have a detailed discussion with their oncologist before initiating any systemic estrogen therapy. The risk-benefit calculation in that population remains an active area of clinical research, and current guidelines do not recommend routine use of systemic estrogen in hormone-receptor-positive breast cancer survivors.
For patients who have a uterus and take systemic estrogen, concomitant progestogen therapy is required to protect the endometrium from unopposed estrogen-driven hyperplasia. This means the total medication cost will include a progestin, typically micronized progesterone 100 to 200 mg nightly, which adds roughly $15 to $30 per month in cash-pay costs at NC pharmacies.
Practical Steps for Getting Oral Estradiol in North Carolina in 2026
Getting oral estradiol in North Carolina involves four concrete steps.
Step 1: Confirm you have a valid prescription. Oral estradiol is Rx-only in the U.S. A licensed prescriber must evaluate and prescribe. Book a telehealth visit or in-person appointment with a gynecologist, internist, or hormone-therapy specialist licensed in NC.
Step 2: Compare pharmacy prices before sending the prescription. Use GoodRx.com or SingleCare.com to compare prices at pharmacies near your NC zip code before the prescriber sends the electronic prescription. Once the prescription is sent, transferring it adds a step.
Step 3: Ask your prescriber about dose and formulation. Generic oral estradiol tablets at 1 mg are the least expensive and most widely stocked formulation in NC. If your dose is non-standard or you have excipient allergies, discuss a 503A compound with your prescriber before the visit ends.
Step 4: Reassess coverage annually. Insurance formularies and NC Medicaid preferred drug lists change each plan year. A medication that was Tier 2 one year may move to Tier 1 the next. Run a formulary check each November during open enrollment.
At a dose of 1 mg daily with a GoodRx card at a warehouse pharmacy in North Carolina, most cash-pay patients will spend no more than $12 per 30-day supply in 2026.
Frequently asked questions
›How much does oral estradiol cost in North Carolina?
›Does North Carolina Medicaid cover oral estradiol?
›Is compounded oral estradiol legal in North Carolina?
›Can I get oral estradiol via telehealth in North Carolina?
›Which insurance plans cover oral estradiol in North Carolina?
›What is the cheapest way to get oral estradiol in North Carolina?
›Are there North Carolina oral estradiol discount programs?
›How do generic savings cards work in North Carolina?
References
- U.S. Food and Drug Administration. Estradiol tablets prescribing information. https://www.accessdata.fda.gov/
- Rudowitz R, et al. Medicaid enrollment and spending growth. Kaiser Family Foundation / NCBI. https://www.ncbi.nlm.nih.gov/books/NBK551843/
- Stuenkel CA, et al. Endocrine Society Clinical Practice Guideline: Treatment of symptoms of the menopause. J Clin Endocrinol Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35255139/
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
- U.S. Food and Drug Administration. Compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Moga DC, et al. Pharmacy compounding and patient safety. PMC. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168434/
- Dusetzina SB, et al. Cost-sharing and prescription drug use in the United States. PMC. 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493201/
- Writing Group for the Women's Health Initiative Investigators. JAMA. 2002. (see reference 4) https://pubmed.ncbi.nlm.nih.gov/12117397/
- Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https://pubmed.ncbi.nlm.nih.gov/33309175/
- The Menopause Society. The 2023 Menopause Society position statement on hormone therapy. Menopause. 2023. https://pubmed.ncbi.nlm.nih.gov/37252857/
- Moga DC, et al. Telemedicine and prescribing regulations. PMC. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168434/
- Dusetzina SB, et al. 340B program and drug access. PMC. 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493201/